Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials

Article ID	Journal	Published Year	Pages	File Type
8453341	Leukemia Research	2018	29 Pages	PDF

Abstract

In conclusion, the combination of LEN/DEX administered to patients with r/r MM in routine clinical practice showed similar effectiveness and safety as demonstrated in the registration trials.

Keywords

CTCAE minimal response VGPR SmPC g/L TTP SAE eCRF ADR ANC PTS ISS DEX TTD ORR ECoG PLA SPM PFs standard deviation Safety progression-free survival overall survival partial remission Patients Thromboembolism Absolute neutrophil count Routine clinical practice LEN summary of product characteristics Second primary malignancy Dexamethasone complete remission Time to progression International Staging System eastern cooperative oncology group adverse event Adverse drug reaction Serious adverse event confidence interval Electronic case report form Lenalidomide Common Terminology Criteria for Adverse Events Multiple myeloma overall response rate hazard ratio Placebo

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research

$Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials$

Authors

Wolfgang Knauf, Ali Aldaoud, Christoph Losem, Johann Mittermueller, Michael Neise, Beate Niemeier, Johanna Harde, Tanja Trarbach, Karin Potthoff,